TD Cowen Maintains Vicarious Surgical(RBOT.US) With Buy Rating, Maintains Target Price $13
BTIG Maintains Vicarious Surgical(RBOT.US) With Hold Rating
Vicarious Surgical Analyst Ratings
Piper Sandler Maintains Neutral on Vicarious Surgical, Lowers Price Target to $8.5
Piper Sandler Remains a Hold on Vicarious Surgical (RBOT)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Vicarious Surgical (RBOT), Alkermes (ALKS) and Zealand Pharma (OtherZLDPF)
Vicarious Surgical's Promising Progress: Buy Rating Affirmed Amid Strategic Milestones and Clinical Advancements
BTIG Maintains Vicarious Surgical(RBOT.US) With Hold Rating
BTIG Sticks to Its Hold Rating for Vicarious Surgical (RBOT)
Vicarious Surgical Is Maintained at Neutral by Piper Sandler
Vicarious Surgical Analyst Ratings
Promising Milestones and Financial Prudence Drive Buy Rating for Vicarious Surgical
TD Cowen Maintains Vicarious Surgical(RBOT.US) With Buy Rating, Raises Target Price to $13
BTIG Maintains Vicarious Surgical(RBOT.US) With Hold Rating
Morgan Stanley Maintains Vicarious Surgical(RBOT.US) With Hold Rating, Cuts Target Price to $6.5
Vicarious Surgical Analyst Ratings
TD Cowen Maintains Vicarious Surgical(RBOT.US) With Buy Rating, Maintains Target Price $10
Piper Sandler Maintains Vicarious Surgical(RBOT.US) With Hold Rating, Cuts Target Price to $12
Piper Sandler Sticks to Their Hold Rating for Vicarious Surgical (RBOT)
Vicarious Surgical's Progress and Upcoming Milestones Merit a Buy Rating